Skip to content

Regeneron Pharmaceuticals REGN Finance Lease Liability, Current

Finance Lease Liability, Current at other companies

Incyte logo
IncyteINCY
$4.41M-1.5%
AbbVie logo
AbbVieABBV
$19M+11.8%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$52K
Kymera Therapeutics logo
Kymera TherapeuticsKYMR

Other financials

Income statement

See full
Revenue$3.6B+19.0%
Operating income$642.9M+8.7%
Net income$727.2M-10.1%
EPS (diluted)$6.75-7.2%

Balance sheet

See full
Cash & equivalents$3.0B-4.0%
Total debt$2.7B+0.1%
Total equity$31.4B+6.9%
Total assets$40.9B+8.9%

Cash flow

See full
Operating cash flow$1.1B+3.2%
CapEx$230.6M+0.6%
Free cash flow$848.3M+4.0%

Valuation

See full
Market cap$63.95B+17.8%
Enterprise value$63.68B+18.1%
P/E14.5×+2.4×
P/S4.3×+0.4×

Profitability

See full
Gross margin93.9%
Operating margin24.3%-2.9pp
Net margin29.6%-2.3pp
FCF margin27.6%+5.5pp

Returns & leverage

See full
Return on equity14.5%-1.4pp
Debt / equity0.1×0.0×
Current ratio3.6×-1.4×

Where this comes from

Reported directly by Regeneron Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityCurrent.

The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Regeneron Pharmaceuticals's finance lease liability, current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Regeneron Pharmaceuticals's finance lease liability, current?
Regeneron Pharmaceuticals (REGN) reported finance lease liability, current of $720M in Q1 2026.
What does finance lease liability, current mean?
Finance lease liabilities (current) represent the portion of lease obligations that are due to be paid within the next twelve months. These obligations arise from long-term contracts where the company effectively controls the leased asset. This metric is critical for assessing near-term liquidity and cash flow requirements.